NovaBridge Biosciences (NBP) Financial Ratios
8 years of historical data (2017–2024) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
N/A
—
5yr avg: 7.57
30Y Low7.6·High7.6
P/B Ratio
↓
6.10
↑+1499% vs avg
5yr avg: 0.38
30Y Low0.1·High0.8
ROE
↓
-16.9%
↓+49% vs avg
5yr avg: -32.9%
30Y Low-66%·High26%
Debt/EBITDA
N/A
—
5yr avg: 0.08
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
NBP Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
NovaBridge Biosciences currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $416M | $69M | $158M | $345M | $3.6B | $3.2B | — | — | — |
| Enterprise Value | $407M | $5M | $-1849440256 | $-2830797744 | $189M | $-1521929173 | — | — | — |
| P/E Ratio → | -3.39 | — | — | — | — | 6.83 | — | — | — |
| P/S Ratio | — | — | 35.25 | — | 40.89 | 2.09 | — | — | — |
| P/B Ratio | 6.10 | 0.34 | 0.09 | 0.11 | 0.78 | 0.57 | — | — | — |
| P/FCF | — | — | — | — | — | 7.57 | — | — | — |
| P/OCF | — | — | — | — | — | 7.43 | — | — | — |
P/E links to full P/E history page with 30-year chart
NBP EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | -412.29 | — | 2.14 | -0.99 | — | — | — |
| EV / EBITDA | — | — | — | — | — | -9.04 | — | — | — |
| EV / EBIT | — | — | — | — | — | -9.78 | — | — | — |
| EV / FCF | — | — | — | — | — | -3.58 | — | — | — |
NBP Profitability
Margins and return-on-capital ratios measuring operating efficiency
Operating margins have compressed from 3422.2% to -11395.1% over the past 3 years, signaling potential cost pressures or competitive headwinds. A negative ROE of -16.9% indicates the company is currently destroying shareholder equity.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 100.0% | 2325.8% | 47.3% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | — | — | -11395.1% | 3422.2% | -2353.1% | 10.1% | -4883.2% | -815.6% | -2431.2% |
| Net Profit Margin | — | — | -32674.0% | 23438.9% | -2648.7% | 30.5% | -4950.0% | -749.0% | -2580.8% |
Return on Capital
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| ROE | -16.9% | -16.9% | -62.0% | -66.0% | -45.6% | 26.2% | — | — | -5043.8% |
| ROA | -11.5% | -11.5% | -43.8% | -51.7% | -39.0% | 11.7% | -72.2% | -23.7% | -29.1% |
| ROIC | — | — | — | -54.4% | -150.9% | 13.2% | — | — | — |
| ROCE | -31.2% | -31.2% | -18.2% | -8.7% | -38.5% | 4.5% | -92.2% | -30.7% | -33.8% |
NBP Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
The company holds a net cash position — cash of $68M exceeds total debt of $4M, providing substantial financial flexibility for buybacks, acquisitions, or weathering downturns.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.08 | 0.01 | 0.02 | 0.00 | — | — | 36.02 |
| Debt / EBITDA | — | — | — | — | — | 0.08 | — | — | — |
| Net Debt / Equity | — | -0.32 | -1.17 | -1.06 | -0.74 | -0.84 | — | — | -16.05 |
| Net Debt / EBITDA | — | — | — | — | — | -28.19 | — | — | — |
| Debt / FCF | — | — | — | — | — | -11.15 | — | — | — |
| Interest Coverage | — | — | -5018.58 | — | — | 1062.06 | -3426.98 | -258.01 | -325.05 |
Net cash position: cash ($68M) exceeds total debt ($4M)
NBP Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
NovaBridge Biosciences's current ratio of 20.90x is well above the 1.0 safety threshold, indicating strong short-term liquidity with ample room to cover current liabilities. The current ratio has improved from 5.50x to 20.90x over the past 3 years.
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 20.90 | 20.90 | 5.67 | 5.50 | 7.66 | 9.28 | 2.31 | 5.88 | 3.54 |
| Quick Ratio | 20.90 | 20.90 | 5.60 | 5.62 | 7.66 | 9.28 | 2.41 | 6.51 | 3.54 |
| Cash Ratio | 20.51 | 20.51 | 5.25 | 5.23 | 6.85 | 8.31 | 1.99 | 5.33 | 2.94 |
| Asset Turnover | — | — | 0.00 | -0.00 | 0.02 | 0.24 | 0.02 | 0.02 | 0.01 |
| Inventory Turnover | 10.87 | — | — | — | 10.87 | — | — | — | — |
| Days Sales Outstanding | — | — | 149.15 | -164.17 | 252.74 | 16.87 | 97.15 | 63.55 | 19.84 |
NBP Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
NovaBridge Biosciences returns 0.0% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | 14.6% | — | — | — |
| FCF Yield | — | — | — | — | — | 13.2% | — | — | — |
| Buyback Yield | 0.0% | 0.5% | 5.5% | 0.9% | 0.0% | 0.2% | — | — | — |
| Total Shareholder Yield | 0.0% | 0.5% | 5.5% | 0.9% | 0.0% | 0.2% | — | — | — |
| Shares Outstanding | — | $81M | $83M | $83M | $76M | $68M | $58M | $58M | $58M |
Peer Comparison
Compare NBP with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 NBPYou | $416M | -3.4 | — | — | — | — | -16.9% | — | — |
 RCUS | $2B | -7.5 | — | — | 96.0% | -156.3% | -63.3% | -64.1% | — |
 KYMR | $7B | -22.9 | — | — | 100.0% | -891.3% | -25.8% | -24.9% | — |
 PRAX | $10B | -24.7 | — | — | — | — | -45.8% | -65.0% | — |
 ARQT | $3B | -158.9 | — | — | 90.2% | -3.3% | -9.3% | -5.2% | — |
 IMVT | $6B | -10.0 | — | — | — | — | -62.5% | — | — |
 VERA | $3B | -7.7 | — | — | — | — | -50.7% | -54.6% | — |
 ACAD | $4B | 9.9 | 26.9 | 36.7 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 INVA | $2B | 6.9 | 8.1 | 9.9 | 72.3% | 38.5% | 29.1% | 14.2% | 1.3 |
 NKTR | $2B | -8.6 | — | — | 100.0% | -236.8% | -217.9% | -57.2% | — |
 PTGX | $6B | -48.2 | — | 113.4 | 97.3% | -343.6% | -20.2% | -21.8% | — |
| Healthcare Median | — | 22.3 | 14.4 | 18.5 | 63.9% | -5.2% | -33.7% | -11.2% | 3.3 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 8 years · Updated daily
See NBP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NBP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NBP vs RCUS
Side-by-side business, growth, and profitability comparison vs Arcus Biosciences, Inc..
Start ComparisonNBP — Frequently Asked Questions
Quick answers to the most common questions about buying NBP stock.
What is NovaBridge Biosciences's P/E ratio?
NovaBridge Biosciences's current P/E ratio is -3.4x. The historical average is 6.8x.
What is NovaBridge Biosciences's ROE?
NovaBridge Biosciences's return on equity (ROE) is -16.9%. The historical average is -32.9%.
Is NBP stock overvalued?
Based on historical data, NovaBridge Biosciences is trading at a P/E of -3.4x. Compare with industry peers and growth rates for a complete picture.